Live feed07:00:00·689dPRReleasevia QuantisnowCytoMed Therapeutics' first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial GrantByQuantisnow·Wall Street's wire, on your screen.GDTC· CytoMed Therapeutics LimitedHealth Care
